VolitionRx Limited (VNRX)
AMEX: VNRX
· Real-Time Price · USD
0.51
0.01 (1.98%)
At close: May 06, 2025, 3:59 PM
0.51
-0.34%
After-hours: May 06, 2025, 05:16 PM EDT
1.98% (1D)
| Bid | 0.51 |
| Market Cap | 51.06M |
| Revenue (ttm) | 1.23M |
| Net Income (ttm) | -26.97M |
| EPS (ttm) | -0.31 |
| PE Ratio (ttm) | -1.63 |
| Forward PE | -12.56 |
| Analyst | Buy |
| Ask | 0.54 |
| Volume | 122,667 |
| Avg. Volume (20D) | 182,970 |
| Open | 0.50 |
| Previous Close | 0.50 |
| Day's Range | 0.49 - 0.53 |
| 52-Week Range | 0.42 - 0.90 |
| Beta | 1.00 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company ope...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Mar 2, 2012
Employees 85
Stock Exchange AMEX
Ticker Symbol VNRX
Website https://www.volition.com
Analyst Forecast
According to 5 analyst ratings, the average rating for VNRX stock is "Buy." The 12-month stock price forecast is $3.75, which is an increase of 640.08% from the latest price.
Stock ForecastsNext Earnings Release
VolitionRx Limited is scheduled to release its earnings on May 20, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+7.39%
VolitionRX shares are trading higher on possible c...
Unlock content with
Pro Subscription
9 months ago
-7.19%
VolitionRx shares are trading lower after the company announced the pricing of its $21.5 million registered direct offering.
